A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

October 31, 2005

Study Completion Date

October 31, 2005

Conditions

Prostatic NeoplasmsMetastases, Neoplasm

Interventions

DRUG

ZD4054 10 mg

1 x 10 mg oral tablets once daily

DRUG

ZD4054 15 mg

1 x 10 mg + 2 x 2.5 mg oral tablets once daily

DRUG

ZD4054 22.5 mg

2 x 10 mg + 2 x 2.5 mg oral tablets once daily

Trial Locations (2)

Research Site, Cleveland

Research Site, Madison